Agomab Therapeutics (AGMB) CFO discloses multiple stock option grants

Rhea-AI Filing Summary

Agomab Therapeutics NV’s Chief Financial Officer Pierre Thadee Victor Kemula reported existing stock option holdings in a Form 3. The filing shows three option awards over 289,005, 102,057 and 191,958 common shares at exercise prices of $2.7600, $3.1800 and $14.2600, expiring between July 8, 2034 and January 15, 2036. Footnotes describe time-based vesting, including one grant where 50% of the underlying shares vested on February 9, 2026 with the balance vesting in 24 monthly installments, and another where 25% vests on February 9, 2027 followed by 36 monthly installments. The options relate to common shares, which may be represented by American Depositary Shares on a one-for-one basis.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Kemula Pierre Thadee Victor

(Last) (First) (Middle)

AGOMAB THERAPEUTICS NV

POSTHOFLEI 1/6

(Street)

ANTWERPEN 2600

(City) (State) (Zip)

BELGIUM

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Agomab Therapeutics NV [ AGMB ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	07/08/2034	Common shares(2)	289,005	$2.76(3)	D
Stock Option (Right to Buy)	(1)	11/04/2034	Common shares(2)	102,057	$3.18(3)	D
Stock Option (Right to Buy)	(4)	01/15/2036	Common shares(2)	191,958	$14.26(3)	D

Explanation of Responses:

1. 50% of the shares underlying this option vested on February 9, 2026, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

2. The common shares may be represented by American Depositary Shares, each of which currently represents one common share.

3. The exercise prices are reported in U.S. dollars and reflect the conversion from EUR to USD at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026.

4. 25% of the shares underlying this option shall vest on February 9, 2027, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Ellen Lefever, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Agomab Therapeutics (AGMB) Form 3 filing show for the CFO?

The Form 3 shows Agomab’s CFO, Pierre Thadee Victor Kemula, reporting existing stock option holdings. It lists three option grants over 289,005, 102,057 and 191,958 common shares with exercise prices in U.S. dollars and expirations between July 2034 and January 2036.

Are there buy or sell transactions in Agomab Therapeutics (AGMB) CFO’s Form 3?

No buy or sell transactions are reported; the entries are holdings. The filing lists stock options already granted to the CFO, including underlying share amounts, exercise prices and expiration dates, rather than new market purchases or sales of Agomab Therapeutics securities.

What are the exercise prices and expirations of the AGMB CFO’s stock options?

The CFO’s options have exercise prices of $2.7600, $3.1800 and $14.2600 per share. They expire on July 8, 2034, November 4, 2034 and January 15, 2036, covering three separate grants tied to Agomab Therapeutics common shares.

How do the vesting schedules work for the AGMB CFO’s stock options?

One option grant vests 50% on February 9, 2026, with the remainder vesting in 24 equal monthly installments. Another grant vests 25% on February 9, 2027, then in 36 equal monthly installments, all subject to the CFO’s continued service with Agomab Therapeutics.

Do Agomab Therapeutics (AGMB) stock options relate to ADSs or ordinary shares?

The options are over common shares of Agomab Therapeutics, which may be represented by American Depositary Shares. Each American Depositary Share currently represents one common share, so the option awards correspond one-for-one with potential ADSs if used in that form.

In what currency are the AGMB CFO’s stock option exercise prices reported?

The exercise prices in the Form 3 are reported in U.S. dollars. A footnote explains they reflect conversion from euros at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026, standardizing disclosure for investors.